Cardiome in deal for commercialization of Brinavess in Israel
Canada-based Cardiome Pharma (TSX: COM) has entered into an agreement with Tzamal Medical to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Under the terms of the accord, Tzamal Medical has agreed to specific annual commercial goals for Brinavess. Financial details of the deal have not been disclosed.
Cardiome recently re-acquired rights to Brinavess, approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, from US drug giant Merck & Co, and has already out-licensed the drug for certain European markets to AOP Orphan (The Pharma Letters June 13 and July 4).
"This agreement with Tzamal Medical reaffirms Cardiome's commitment to continue making Brinavess available worldwide, including markets outside of Europe," said Karim Lalji , Cardiome's chief commercial officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze